Vaccinex (NASDAQ:VCNX) Trading Down 6.4% – Here’s Why

Vaccinex, Inc. (NASDAQ:VCNX)’s share price fell 6.4% on Tuesday . The stock traded as low as $1.03 and last traded at $1.03. 289 shares traded hands during trading, a decline of 91% from the average session volume of 3,084 shares. The stock had previously closed at $1.10.

Vaccinex Stock Down 6.4%

The firm has a 50 day moving average of $1.13 and a 200-day moving average of $0.80. The company has a market cap of $2.68 million, a P/E ratio of -0.02 and a beta of 1.10.

Vaccinex Company Profile

Vaccinex, Inc is a clinical-stage biopharmaceutical company developing novel immunotherapies targeting oncology and neurodegenerative diseases. Headquartered in Rochester, New York, Vaccinex harnesses its proprietary human antibody platform to modulate the semaphorin 4D (SEMA4D) pathway, a mechanism implicated in tumor immune evasion and neuroinflammatory processes. Its lead asset, pepinemab (VX15/2503), is an investigational monoclonal antibody designed to bind and block SEMA4D, thereby promoting immune cell infiltration in tumors and supporting neural repair in degenerative disorders.

In oncology, Vaccinex has advanced pepinemab through Phase 2 trials in solid tumors and hematologic malignancies, exploring its potential to enhance the efficacy of established checkpoint inhibitors.